With the BARDA contract, PPD will be evaluating the long-term stability of vaccines for avian influenza within the U.S. Centers for Disease Control and Prevention’s (CDC) Strategic National Stockpile (SNS). This form of influenza is considered to be a high-risk pathogen, as it can cause serious illness and even death. It is typically spread through contact with sick poultry and wildlife, and it is rare for the disease to spread among people.
The U.S. Army contract will entail the research and development of medical products that give U.S. military forces the ability to foster preparedness efforts, as well as provide service members with high-quality preventive care and other forms of treatment.
“PPD is pleased to contribute to the important missions of improving health outcomes for armed-services personnel and helping protect the people of the United States against the threat of pandemic influenza,” Bill Sharbaugh, chief operating officer of PPD, said. “Our integrated services, including deep clinical and laboratory expertise, enable us to provide the medical and technical knowledge necessary to help ensure these vital programs succeed.”